NEUMORA THERAPEUTICS, INC. Comprehensive Income
NEUMORA THERAPEUTICS, INC. (NMRA) reported Comprehensive Income of -$43.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$43.08M.
- NEUMORA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$53.46M.
- NEUMORA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$59.46M.
- NEUMORA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$56.73M.
- NEUMORA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$236.99M.
- NEUMORA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$243.65M.
- NEUMORA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$235.23M.
- NEUMORA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$131.68M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$43.08M 10-Q · filed 2026-08-14 | -$96.54M 10-Q · filed 2026-08-14 | -$156.00M derived: sum of 3 quarters · filed 2026-08-14 | -$212.73M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$53.46M 10-Q · filed 2026-05-07 | -$112.92M derived: sum of 2 quarters · filed 2026-05-07 | -$169.65M derived: sum of 3 quarters · filed 2026-05-07 | -$222.39M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$59.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$116.19M derived: sum of 2 quarters · filed 2026-03-30 | -$168.93M derived: sum of 3 quarters · filed 2026-08-14 | -$236.99M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$56.73M 10-Q · filed 2025-11-06 | -$109.47M derived: sum of 2 quarters · filed 2026-08-14 | -$177.53M 10-Q · filed 2025-11-06 | -$236.39M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$52.74M 10-Q · filed 2026-08-14 | -$120.80M 10-Q · filed 2026-08-14 | -$179.66M derived: sum of 3 quarters · filed 2026-08-14 | -$251.92M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$68.06M 10-Q · filed 2026-05-07 | -$126.92M derived: sum of 2 quarters · filed 2026-05-07 | -$199.17M derived: sum of 3 quarters · filed 2026-05-07 | -$257.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$58.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$131.12M derived: sum of 2 quarters · filed 2026-03-30 | -$189.86M derived: sum of 3 quarters · filed 2026-03-30 | -$243.65M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$72.25M 10-Q · filed 2025-11-06 | -$130.99M derived: sum of 2 quarters · filed 2025-11-06 | -$184.79M 10-Q · filed 2025-11-06 | -$293.28M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$58.74M 10-Q · filed 2025-08-06 | -$112.53M 10-Q · filed 2025-08-06 | -$221.03M derived: sum of 3 quarters · filed 2025-08-06 | -$273.92M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$53.79M 10-Q · filed 2025-05-12 | -$162.29M derived: sum of 2 quarters · filed 2025-05-12 | -$215.18M derived: sum of 3 quarters · filed 2025-05-12 | -$253.87M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$108.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$161.38M derived: sum of 2 quarters · filed 2025-03-03 | -$200.08M derived: sum of 3 quarters · filed 2025-03-03 | -$235.23M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$52.89M 10-Q · filed 2024-11-12 | -$91.58M derived: sum of 2 quarters · filed 2024-11-12 | -$126.73M 10-Q · filed 2024-11-12 | -$154.50M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$38.69M 10-Q · filed 2024-08-06 | -$73.84M 10-Q · filed 2024-08-06 | -$101.61M derived: sum of 3 quarters · filed 2025-03-03 | -$131.24M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$35.15M 10-Q · filed 2024-05-07 | -$62.91M derived: sum of 2 quarters · filed 2025-03-03 | -$92.54M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$27.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$57.39M derived: sum of 2 quarters · filed 2025-03-03 | -$131.68M 10-K · filed 2025-03-03 | |
| 2022-09-30 | -$29.63M 10-Q · filed 2023-11-01 | -$103.91M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |